查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589597

药物和基因输送设备市场：按给药途径、方法和载体分类 - 全球预测 2025-2030

Drug & Gene Delivery Devices Market by Route of Administration (Inhalation, Injectable, Nasal), Method (Ex vivo, In situ), Vector - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年药物和基因输送设备市值为43.3亿美元，预计到2024年将达到47.9亿美元，复合年增长率为10.72%，到2030年将达到88.3亿美元。

药物和基因传递设备市场包括各种用于将药物化合物或遗传物质直接输送到患者体内的系统，以最小的副作用实现标靶治疗。未来的前景在于精准医学的进步，这些设备在慢性病和遗传性疾病的个人化治疗中发挥着至关重要的作用。慢性病和遗传疾病的日益普及以及对微创输送技术的日益重视推动了对这些医疗设备的需求。应用因治疗领域而异，例如癌症、糖尿病和感染疾病，最终用途包括医院、诊所和居家医疗。影响市场的主要成长要素包括生物技术的进步、对生技药品不断增长的需求以及提高给药效率和患者依从性的奈米技术创新。最近的发展表明，开发生物分解性的智慧型药物传输系统具有潜在的机会，这些系统可响应生理条件进行控制释放。

主要市场统计
基准年[2023] 43.3亿美元
预测年份 [2024] 47.9亿美元
预测年份 [2030] 88.3亿美元
复合年增长率（%） 10.72%

挑战包括监管障碍、高开发成本和潜在的生物相容性问题。此外，我们也受到关键药品专利到期和严格的品管要求的限制。市场竞争激烈，有大量的研发机会专注于改善递送机制，例如用于基因转移的微针、水凝胶和非病毒载体。鼓励相关人员投资最尖端科技和跨行业合作，以改善设备功能和患者治疗效果。为了利用新机会，公司可以探索伙伴关係，利用人工智慧和巨量资料分析来改善个人化交付系统。创新最好集中在整合诊断和治疗能力的多功能输送平台上，从而提高疗效和患者依从性。精准医学和生技药品不断发展的格局需要持续的研究和创新，为策略市场切入点和持续的业务成长铺平道路。

市场动态：快速发展的药物和基因输送设备市场的关键市场洞察

药物和基因输送设备市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 心血管疾病 (CVD) 和文明病的盛行率上升
    • 自动注射器和先进肺部设备简介
    • 药品和治疗药物的消费量增加
  • 市场限制因素
    • 併发症增加，提供治疗和药物所需的专业知识
  • 市场机会
    • 药物传递和基因传递系统领域的进展，包括智慧奈米颗粒技术、脂质体和水凝胶以及3D列印
    • 持续增加基因组学领域的研究和开发，以开发基因传递系统
  • 市场挑战
    • 高端产品成本增加

波特五力：驾驭药物与基因传递设备市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解药物和基因输送设备市场的外部影响

外部宏观环境因素在塑造药物和基因传递设备市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解药物和基因输送设备市场的竞争格局

药物和基因输送设备市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵药物和基因传输设备市场供应商的绩效评估

FPNV 定位矩阵是评估药物和基因传递设备市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划药物和基因输送设备市场的成功之路

药物和基因输送设备市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病 (CVD) 和文明病的盛行率上升
      • 自动注射器和先进肺部装置简介
      • 药品和治疗药物的消费量增加
    • 抑制因素
      • 提供治疗和药物所需的复杂性和专业知识不断增加
    • 机会
      • 智慧奈米颗粒技术、脂质体和水凝胶以及3D列印等药物和基因传递系统领域的进展
      • 持续增加基因组学领域的研究和开发，以开发基因传递系统
    • 任务
      • 奢侈品成本上涨
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 药物与基因递送设备市场：依管理途径

  • 吸入
  • 可注射的
  • 鼻腔
  • 眼科
  • 口服
  • 话题
  • 经皮

第七章药物和基因递送设备市场：依方法

  • 体外
  • 当地的

第 8 章药物与基因递送设备市场载体

  • 非病毒性
  • 病毒性的

第九章美洲药物与基因传递设备市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太药物与基因传递设备市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲/中东/非洲药物与基因传递设备市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 3M Company
  • Antares Pharma, Inc.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Eisai Co., Ltd.
  • Enable Injections, Inc.
  • Gerresheimer AG
  • Insulet Corporation
  • Johnson & Johnson Services Inc.
  • Koninklijke Philips NV
  • Merck KGaA
  • OraSure Technologies, Inc.
  • Oxford BioMedica PLC
  • Sanofi SA
Product Code: MRR-A86604082727

The Drug & Gene Delivery Devices Market was valued at USD 4.33 billion in 2023, expected to reach USD 4.79 billion in 2024, and is projected to grow at a CAGR of 10.72%, to USD 8.83 billion by 2030.

The market for Drug & Gene Delivery Devices encompasses a wide range of systems used to deliver pharmaceutical compounds and genetic materials directly into a patient's system, ensuring targeted therapy with minimal side effects. Future scope lies in advancing precision medicine, where these devices could become pivotal in personalized treatments for chronic and genetic diseases. The necessity for these devices stems from the growing prevalence of chronic and genetic disorders and an increasing emphasis on minimally invasive delivery techniques. Applications vary across therapeutic areas, including oncology, diabetes, and infections, with end-use segments covering hospitals, clinics, and home care settings. Key growth factors influencing the market include advancements in biotechnology, growing demand for biologics, and innovations in nanotechnology which enhance delivery efficacy and patient compliance. Recent trends suggest potential opportunities in developing biodegradable and smart drug delivery systems that respond to physiological conditions for controlled release.

KEY MARKET STATISTICS
Base Year [2023] USD 4.33 billion
Estimated Year [2024] USD 4.79 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 10.72%

Challenges include regulatory hurdles, high development costs, and potential biocompatibility issues. Limitations are further imposed by patent expirations of major drugs and stringent quality control requirements. The market exhibits a competitive nature, with substantial opportunities in research and development focused on improving delivery mechanisms such as micro-needles, hydrogels, and non-viral vectors for gene delivery. Stakeholders are encouraged to invest in cutting-edge technologies and cross-industry collaborations to enhance device functionality and patient outcomes. To capitalize on emerging opportunities, firms can explore partnerships for leveraging AI and big data analytics in improving personalized delivery systems. Innovations are best focused on multifunctional delivery platforms that integrate diagnostics and therapeutic functions, thereby strengthening efficacy and patient adherence. The evolving landscape in precision medicine and biologics demands continuous research and innovation, paving the way for strategic market entry points and sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug & Gene Delivery Devices Market

The Drug & Gene Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
    • Introduction of auto-injectors and advanced pulmonary devices
    • Rise in the consumption of drugs and therapeutic pharmaceuticals
  • Market Restraints
    • Increase in complications and expertise required in delivering therapeutics and drugs
  • Market Opportunities
    • Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
    • Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
  • Market Challenges
    • Increasing cost of high-end products

Porter's Five Forces: A Strategic Tool for Navigating the Drug & Gene Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug & Gene Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug & Gene Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug & Gene Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug & Gene Delivery Devices Market

A detailed market share analysis in the Drug & Gene Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug & Gene Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug & Gene Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug & Gene Delivery Devices Market

A strategic analysis of the Drug & Gene Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug & Gene Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Antares Pharma, Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Eisai Co., Ltd., Enable Injections, Inc., Gerresheimer AG, Insulet Corporation, Johnson & Johnson Services Inc., Koninklijke Philips N.V., Merck KGaA, OraSure Technologies, Inc., Oxford BioMedica PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Drug & Gene Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Inhalation, Injectable, Nasal, Ocular, Oral, Topical, and Transdermal.
  • Based on Method, market is studied across Ex vivo and In situ.
  • Based on Vector, market is studied across Non-viral and Viral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
      • 5.1.1.2. Introduction of auto-injectors and advanced pulmonary devices
      • 5.1.1.3. Rise in the consumption of drugs and therapeutic pharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. Increase in complications and expertise required in delivering therapeutics and drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
      • 5.1.3.2. Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing cost of high-end products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug & Gene Delivery Devices Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Inhalation
  • 6.3. Injectable
  • 6.4. Nasal
  • 6.5. Ocular
  • 6.6. Oral
  • 6.7. Topical
  • 6.8. Transdermal

7. Drug & Gene Delivery Devices Market, by Method

  • 7.1. Introduction
  • 7.2. Ex vivo
  • 7.3. In situ

8. Drug & Gene Delivery Devices Market, by Vector

  • 8.1. Introduction
  • 8.2. Non-viral
  • 8.3. Viral

9. Americas Drug & Gene Delivery Devices Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Drug & Gene Delivery Devices Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Drug & Gene Delivery Devices Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Antares Pharma, Inc.
  • 3. B. Braun SE
  • 4. Baxter International Inc.
  • 5. Becton, Dickinson and Company
  • 6. Eisai Co., Ltd.
  • 7. Enable Injections, Inc.
  • 8. Gerresheimer AG
  • 9. Insulet Corporation
  • 10. Johnson & Johnson Services Inc.
  • 11. Koninklijke Philips N.V.
  • 12. Merck KGaA
  • 13. OraSure Technologies, Inc.
  • 14. Oxford BioMedica PLC
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. DRUG & GENE DELIVERY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG & GENE DELIVERY DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY OCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY IN SITU, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 148. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023